Celyad Oncology SA

CYAD

Company Profile

  • Business description

    Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.

  • Contact

    Rue Edouard Belin 2
    Axis Business Park
    Brabant Wallon
    Mont-Saint-Guibert1435
    BEL

    T: +32 10394100

    E: [email protected]

    https://www.celyad.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    39

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,655.2023.700.27%
CAC 407,826.791.34-0.02%
DAX 4024,226.49198.840.83%
Dow JONES (US)42,343.65740.581.78%
FTSE 1008,778.0560.080.69%
HKSE23,343.6338.36-0.16%
NASDAQ19,199.16461.962.47%
Nikkei 22537,938.09213.980.57%
NZX 50 Index12,370.03212.30-1.69%
S&P 5005,921.54118.722.05%
S&P/ASX 2008,426.1018.500.22%
SSE Composite Index3,340.830.140.00%

Market Movers